US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to “administrative constraints” at the Food and Drug Administration, the company said.
The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA-1345, ...
Novavax stock popped Friday on news of a licensing deal and minority stake from Big Pharma player Sanofi. Moderna stock toppled Friday after the FDA delayed an approval decision on its RSV vaccine ...